New Zealand markets closed

G1 Therapeutics, Inc. (GTHX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.16+0.22 (+4.45%)
As of 03:46PM EDT. Market open.

G1 Therapeutics, Inc.

700 Park Offices Drive
Suite 200
Research Triangle Park, NC 27709
United States
919 213 9835

Full-time employees148

Key executives

NameTitlePayExercisedYear born
Mr. John E. Bailey Jr.CEO, Pres & Director1.04MN/A1965
Ms. Jennifer K. Moses CPAChief Financial Officer606.27k58.05k1975
Dr. Mark A. Velleca M.D., Ph.D.Sr. Advisor & Director242.69kN/A1964
Dr. Rajesh K. Malik Ch.B., M.B., M.D.Chief Medical Officer and Sr. VP of R&D596.37k1.48M1959
Mr. Mark AvaglianoChief Bus. Officer606.05kN/A1976
Mr. Andrew PerryChief Commercial Officer568.6kN/A1973
Mr. Terry L. MurdockChief Operating OfficerN/AN/A1960
Mr. Alexander D. Smith M.S.VP of Technical OperationsN/AN/AN/A
Dr. Jay C. Strum Ph.D.Chief Scientific OfficerN/AN/A1964
Mr. William C. RobertsVP of Investor Relations & Corp. CommunicationsN/AN/A1969
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.

Corporate governance

G1 Therapeutics, Inc.’s ISS governance QualityScore as of 1 June 2022 is 8. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.